Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hyslink Therapeutics currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is being handled by 1 distinct examiner and is located within 1 distinct art unit. This indicates a very specific and singular point of contact for the company's current patent prosecution efforts.
AGGARWAL, SAHIL CHANDER is the busiest examiner for this portfolio, with 1 busiest examiner pending action. Since the total number of pending office actions is 1, this examiner is responsible for the entirety of the company's current pending workload. This direct relationship between the portfolio's status and the 1 distinct examiner simplifies the prosecution strategy to a single interaction.
The presence of 1 distinct art unit for the pending action suggests a highly focused examination environment. There is no distribution of work across different departments, which means the company's immediate outcomes in the Biotechnology & Pharmaceuticals sector depend on the findings of AGGARWAL, SAHIL CHANDER. This profile reflects a portfolio with a single active point of review at the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AGGARWAL, SAHIL CHANDER | 1 | 66.7% | +0.0% |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18557454 | PREPARATION METHOD FOR ANTIBODY-DRUG CONJUGATE, AND APPLICATION | AGGARWAL, SAHIL CHANDER | 1623 | §103 | Non-Final OA | — | Pending | Oct 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHyslink Therapeutics has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sahil Chander Aggarwal has the most, with 1 of Hyslink Therapeutics's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
